Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Allogene Therapeutics, Inc.
< Previous
1
2
Next >
Allogene Therapeutics Announces Participation in December Investor Conference
December 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
November 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
November 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
November 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
November 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in November Investor Conferences
October 30, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
October 26, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
October 16, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 27, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
September 05, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Appoints Earl Douglas as General Counsel
August 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
August 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
June 15, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Departure of Chief Financial Officer
June 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
June 09, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
May 24, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
May 11, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
April 25, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
April 20, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
April 17, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
April 13, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
March 30, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
March 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
March 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
March 01, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.